Last updated: August 2, 2026
Carbinoxamine maleate is an old, low-cost, first-generation antihistamine with limited molecule-level exclusivity and a stronger commercial case in pediatric liquids, extended-release delivery, taste masking, and differentiated packaging. The main opportunities are reformulation and lifecycle management rather than new chemical-entity protection.
What is the commercial position of carbinoxamine maleate?
Carbinoxamine maleate is an H1 antihistamine used for allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, and mild uncomplicated allergic skin manifestations. It is sedating and has anticholinergic effects, which restrict broad substitution for newer second-generation antihistamines.
The commercial product landscape is centered on oral liquids:
| Product |
Dosage form |
Strength |
Commercial positioning |
Primary source |
| Karbinal ER |
Extended-release oral suspension |
4 mg/5 mL |
Twice-daily pediatric and adult liquid |
FDA label |
| RyClora |
Oral solution |
1 mg/5 mL |
Immediate-release liquid |
FDA label |
| Palgic |
Oral solution |
Historical product |
Legacy immediate-release liquid |
FDA product records |
| Generic carbinoxamine |
Tablets and oral liquids, depending on market availability |
Varies |
Price-driven substitution |
FDA Orange Book and product databases |
Karbinal ER is associated with Tris Pharma’s extended-release liquid technology. RyClora is associated with FSC Laboratories. Product-level revenue is not generally disclosed separately by the manufacturers, so the commercial opportunity is best assessed through dosage-form differentiation, pharmacy access, and pediatric use rather than reported brand sales.
What excipients are used in carbinoxamine maleate products?
The principal excipient strategies differ between immediate-release solutions and extended-release suspensions.
Immediate-release oral solution
A typical carbinoxamine oral solution may use:
- Purified water as the vehicle
- Sorbitol as a sweetening and bulking agent
- Glycerin as a co-solvent and humectant
- Citric acid and sodium citrate for pH control
- Sodium benzoate as a preservative
- Sucralose for high-intensity sweetness
- Flavoring agents
- In some products, viscosity modifiers or solubilizing aids
RyClora’s listed excipients include sorbitol, glycerin, sodium citrate, citric acid, sodium benzoate, sucralose, flavor, and purified water.[1]
This composition supports a sugar-free, alcohol-free pediatric liquid. The trade-off is that sorbitol can cause gastrointestinal discomfort or laxative effects, particularly at higher volumes or in sensitive pediatric patients.
Extended-release oral suspension
Karbinal ER uses a suspension-based delivery system rather than a simple aqueous solution. Its excipient profile includes:
- Microcrystalline cellulose
- Carboxymethylcellulose sodium
- Sorbitol
- Glycerin
- Sodium citrate
- Citric acid
- Sodium benzoate
- Sucralose
- Flavor
- Purified water
Microcrystalline cellulose and carboxymethylcellulose sodium provide suspension structure and help control the release profile. The system must maintain dose uniformity after storage, shaking, pouring, and repeated use. The formulation also requires control of sedimentation, redispersibility, viscosity, particle size, and rheology.[2]
Which excipient strategies create the strongest commercial differentiation?
The most valuable formulation improvements are those that address pediatric adherence, dosing accuracy, shelf stability, and administration frequency.
1. Taste masking
Carbinoxamine has a bitter pharmaceutical taste. Taste masking can be pursued through:
- Optimized sucralose and flavor systems
- Polymer coating of suspended particles
- Ion-exchange resin complexes
- Microencapsulation
- pH adjustment within the stability and tolerability range
- Use of flavor systems compatible with preservatives and suspension polymers
Taste masking is commercially meaningful because caregivers may stop treatment when children reject the product. A flavor system alone is easy to design around. A robust taste-masked particle architecture can provide stronger formulation differentiation.
2. Low-sugar and sugar-free positioning
A sugar-free product has advantages for pediatric use, dental health, and patients limiting sucrose. Sorbitol is a common substitute but may create gastrointestinal tolerability issues. Alternative strategies include:
- Reduced-sorbitol systems
- Mannitol-based formulations
- Xylitol-containing systems
- Polyol combinations
- High-intensity sweeteners paired with structured flavor masking
Any alternative must be evaluated for laxation, osmolarity, crystal formation, viscosity, and taste persistence.
3. Alcohol-free and propylene-glycol-free formulation
Caregivers often prefer products without ethanol or propylene glycol. These solvents can assist solubilization and preservation but may create pediatric labeling and tolerability concerns. A fully aqueous system using buffer, preservative, sweetener, and suspension technology can support a cleaner product profile.
4. Dosing-volume reduction
A concentrated liquid can reduce administration volume. This has direct adherence value, but concentration changes must address:
- Solubility or suspension capacity
- Dose uniformity
- Viscosity and pourability
- Measuring-device accuracy
- Taste intensity
- Maximum daily exposure to excipients
- Labeling and medication-error risk
A 1 mg/5 mL solution requires a larger volume than a 4 mg/5 mL product. A concentrated immediate-release liquid could compete with existing products if it remains easy to measure and acceptable to children.
5. Extended-release delivery
Extended release is the clearest existing formulation differentiation. A twice-daily product can compete against immediate-release dosing by reducing administration frequency. Relevant technologies include:
- Polymer-controlled release
- Ion-exchange resin complexes
- Coated microparticles
- Matrix suspensions
- Multiparticulate systems
The commercial value depends on whether the release profile provides meaningful dosing convenience without excessive sedation or prolonged adverse effects. Extended-release formulations also face greater development risk because the product must demonstrate consistent in vitro and in vivo release.
What formulation patents protect carbinoxamine products?
The active ingredient itself is old and does not provide a realistic composition-of-matter exclusivity opportunity. Protection is more likely to arise from:
- Extended-release particle architecture
- Polymer composition
- Manufacturing process
- Suspension rheology
- Taste-masked particles
- Specific dosing regimens
- Container-closure systems
- Drug-device combinations
- Stability and preservative systems
Karbinal ER’s commercial differentiation is tied to its extended-release oral suspension technology rather than to new molecular exclusivity.[2] A formulation patent can be commercially relevant even when the drug substance is off-patent, but its practical value depends on claim scope, Orange Book listing, expiration, prosecution history, and whether an ANDA applicant can design around the claims.
Patent strength should be assessed claim by claim. Broad claims covering any extended-release carbinoxamine suspension are vulnerable to validity and written-description challenges. Narrow claims tied to defined particle sizes, polymer ratios, release testing, or manufacturing conditions may be harder to invalidate but easier to design around.
When does carbinoxamine maleate lose exclusivity?
Carbinoxamine maleate has no meaningful new-molecule exclusivity remaining. The drug was approved decades ago in earlier products, and commercial barriers now arise from product-specific formulation rights, trademarks, manufacturing know-how, and regulatory positioning.
| Exclusivity category |
Current relevance |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not a central product feature |
| Pediatric exclusivity |
Not expected to create a current market barrier |
| Data exclusivity |
Expired for the legacy active ingredient |
| Formulation patents |
Potentially relevant for extended-release products |
| Method-of-use patents |
Potentially relevant but generally narrower |
| Trademark protection |
Relevant to branded positioning, not generic substitution |
| Trade secrets |
Relevant to particle engineering, flavor systems, and manufacturing |
Patent expiration dates must be confirmed against the current FDA Orange Book patent and exclusivity records for each NDA.[3] A sponsor should not infer patent protection from the presence of a branded product alone.
What is the FDA regulatory status of carbinoxamine products?
Carbinoxamine products are regulated as prescription drug products in the United States. FDA-approved labeling identifies the drug for allergic conditions and includes pediatric dosing for specified age groups.[1,2]
The main regulatory issues for a new product are:
- ANDA eligibility for a therapeutically equivalent immediate-release product
- 505(b)(2) eligibility for a differentiated strength, formulation, or delivery profile
- Bioequivalence for immediate-release solutions
- Comparative pharmacokinetic evaluation for extended-release products
- In vitro release characterization
- Dose uniformity after shaking and storage
- Preservative effectiveness
- Pediatric excipient safety
- Stability after opening
- Accurate dosing-device performance
A simple oral solution may be suitable for an ANDA if a reference-listed drug and matching conditions are available. A novel extended-release suspension, concentrated liquid, or taste-masked product may fit better under the 505(b)(2) pathway.
How many patents cover carbinoxamine maleate?
The drug substance is not supported by a meaningful modern composition-of-matter estate. The relevant patent count is product-specific and depends on whether the analysis includes expired patents, pending applications, unlisted manufacturing patents, and international rights.
The commercially important distinction is:
| Patent category |
Expected competitive impact |
| Carbinoxamine molecule patents |
Minimal |
| Immediate-release solution patents |
Low unless tied to a narrow technical feature |
| Extended-release formulation patents |
Potentially material |
| Taste-masking patents |
Moderate, with design-around potential |
| Manufacturing patents |
Moderate, especially for complex multiparticulates |
| Method-of-use patents |
Usually limited for generic allergy indications |
| Device and packaging patents |
Low to moderate |
A freedom-to-operate review should examine U.S. patents assigned to the sponsors of Karbinal ER and other branded products, then compare the claims with the proposed formulation. FDA Orange Book listing is important because listed patents can trigger Paragraph IV litigation and a potential 30-month stay.[3,4]
Which companies are challenging carbinoxamine products?
Generic competition is most likely for immediate-release oral solutions and tablets because the active ingredient is established and the formulation technology is relatively accessible. Potential ANDA applicants would typically include established generic manufacturers with liquid-dose manufacturing capability.
A confirmed challenger analysis requires review of:
- Current Orange Book entries
- ANDA approval records
- Paragraph IV certifications
- Abbreviated new drug application litigation
- Commercial availability by National Drug Code
- Product discontinuation notices
No biosimilar pathway applies. Carbinoxamine is a small-molecule drug, not a biologic. Competitive risk is therefore generic substitution and 505(b)(2) reformulation, not biosimilar entry.
What patent litigation and settlement risks affect carbinoxamine?
The principal litigation risk would arise from a Paragraph IV certification against an Orange Book-listed formulation patent. The likely dispute areas are:
- Whether a generic extended-release suspension practices the asserted claims
- Obviousness of combining known antihistamine and suspension excipients
- Written description and enablement
- Infringement based on release-profile testing
- Whether a proposed formulation is materially different from the reference product
- The scope of any settlement or license agreement
Immediate-release products face lower litigation risk unless the reference product has an active listed patent. A settlement could grant a delayed generic launch date, authorize an alternative formulation, or permit entry subject to manufacturing or supply conditions.
No major publicly established licensing transaction is central to the carbinoxamine market. The more likely commercial structures are contract manufacturing, authorized generic arrangements, formulation-technology licenses, or brand-to-generic supply agreements.
What commercial opportunities exist for new carbinoxamine formulations?
The strongest opportunities are concentrated in products that improve administration rather than attempt to compete solely on price.
Pediatric oral solution
A new immediate-release solution could compete through:
- Better taste
- Lower administration volume
- Preservative optimization
- Reduced polyol load
- Graduated oral syringe compatibility
- Longer in-use stability
- Lower cost of goods
- Retail and mail-order pharmacy availability
Extended-release suspension
A second extended-release product could compete through:
- Once-daily or improved twice-daily dosing
- More consistent release
- Lower sedimentation
- Easier redispersion
- Smaller bottle volume
- Improved flavor
- Lower viscosity
- A simpler manufacturing process
Unit-dose packaging
Unit-dose cups or sachets could reduce dosing errors and improve portability. The cost is higher packaging expense and potential waste. This model may work in pediatric clinics, urgent-care settings, institutional pharmacies, and travel-oriented consumer segments.
Combination products
A carbinoxamine combination with a decongestant or another allergy ingredient could create commercial differentiation, but regulatory and safety risks are substantial. Sedation, anticholinergic burden, cardiovascular effects from decongestants, and pediatric labeling limitations would narrow the target market.
Global and regional licensing
Opportunities may exist in countries where first-generation antihistamines remain widely used and pediatric liquid access is limited. The most transferable assets are:
- Formulation know-how
- Flavor systems
- Suspension manufacturing
- Local regulatory dossiers
- Brand rights
- Regional supply agreements
Geographic patent coverage is likely to be weaker than for newer drugs because the active ingredient is old. Commercial exclusivity may instead depend on local registration, trademarks, manufacturing capacity, and distribution.
How strong is the carbinoxamine patent estate?
The estate is weak at the molecule level and potentially moderate for technically differentiated liquid products. Its strength depends on whether claims cover an essential product attribute that competitors cannot easily reproduce.
| Estate component |
Relative strength |
| Active ingredient |
Low |
| Basic oral solution |
Low |
| Pediatric taste masking |
Moderate |
| Extended-release suspension |
Moderate to high if claims are narrow and technically validated |
| Manufacturing process |
Moderate |
| Method of use |
Low to moderate |
| Trademark and brand |
Moderate commercially, limited against ANDA substitution |
The best protection strategy combines patent claims with regulatory exclusivity where available, trade secrets covering manufacturing parameters, differentiated packaging, and a reliable supply chain.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible:
- Immediate-release generic entry occurs first, placing price pressure on oral solutions and tablets.
- A 505(b)(2) applicant launches a differentiated concentrated or extended-release liquid.
- The branded extended-release product retains a niche through pediatric prescribing, convenience, taste, and pharmacy relationships despite generic immediate-release competition.
The highest exposure is in undifferentiated oral liquids. The lowest exposure is in a well-protected multiparticulate suspension with meaningful clinical or adherence advantages and difficult-to-replicate manufacturing.
Key Takeaways
- Carbinoxamine maleate is an old, off-patent antihistamine with limited molecule-level exclusivity.
- The leading commercial opportunities are pediatric liquid reformulation, taste masking, reduced dosing volume, and extended release.
- Sorbitol, glycerin, citrate buffers, sodium benzoate, sucralose, and suspension polymers are central excipient tools.
- Extended-release suspensions create more defensible differentiation than basic oral solutions.
- A new immediate-release product may qualify for an ANDA, while a novel delivery system may fit a 505(b)(2) strategy.
- Generic risk is materially higher for simple solutions than for complex multiparticulate suspensions.
- Biosimilar risk does not apply.
- Patent value depends on claim scope, Orange Book listing, expiration, and design-around difficulty.
- Product-level revenue exposure is not publicly disclosed in a reliable standalone format.
FAQs
Is carbinoxamine maleate suitable for a sugar-free pediatric formulation?
Yes. Sugar-free liquids can use sorbitol, glycerin, sucralose, or alternative polyol systems. The formulation must control gastrointestinal tolerability, sweetness, viscosity, and preservative performance.
Can carbinoxamine maleate be developed as a once-daily product?
Potentially, but a once-daily product would require a new controlled-release formulation and supporting pharmacokinetic and clinical data. It would likely be a 505(b)(2) development rather than a straightforward ANDA.
Which excipient creates the main formulation risk?
For immediate-release liquids, the key risks are taste masking, preservative effectiveness, and polyol tolerability. For extended-release suspensions, the principal risks are redispersibility, dose uniformity, release control, and long-term physical stability.
Is a carbinoxamine oral solution likely to receive Paragraph IV certification?
Only if the reference product has a relevant unexpired Orange Book-listed patent. A generic applicant must review the current listing for the specific reference NDA before selecting a certification strategy.
Can a manufacturer obtain exclusivity through a new carbinoxamine flavor?
A flavor change alone is unlikely to provide meaningful regulatory exclusivity. Stronger protection requires a technically meaningful formulation feature, such as a novel taste-masked particle, controlled-release system, or manufacturing process.
References
- U.S. Food and Drug Administration. (2017). RyClora: Carbinoxamine maleate oral solution prescribing information.
- U.S. Food and Drug Administration. (2023). Karbinal ER: Carbinoxamine maleate extended-release oral suspension prescribing information. Tris Pharma, Inc.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
- U.S. Food and Drug Administration. (2024). Submitting “Paragraph IV” certifications for patent listings. Center for Drug Evaluation and Research.
- U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
- U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.
